A Study to Determine the Prevalence and Clinical Characteristics Associated With PKD1 Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Active_not_recruiting
Location: See all (45) locations...
Study Type: Observational
SUMMARY
The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 65
Healthy Volunteers: f
View:
• Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 30 milliliter per minute (mL/min)/1.73 m\^2
• Willing and able to comply with scheduled visits and other study procedures
• A pre-existing diagnosis of ADPKD as defined in the protocol
Locations
United States
Alabama
Alabama Kidney Research
Alabaster
University of Alabama at Birmingham- Nephrology Research Clinic
Birmingham
California
Kaiser Permanente - Los Angeles Medical Center
Los Angeles
UCLA Division of Nephrology
Los Angeles
Helen Diller Medical Center at Parnassus Heights
San Francisco
Connecticut
Nephrology & Hypertension Associates, PC
Middlebury
Yale Nephrology Clinical Research Clinic
New Haven
Florida
Nature Coast Clinical Research - Inverness
Inverness
Mayo Clinic - Jacksonville
Jacksonville
Georgia
Emory School of Medicine - Renal Division
Atlanta
Renal Associates, LLC
Columbus
Iowa
University of Iowa Health Care Medical Center- Nephrology
Iowa City
Illinois
UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology
Chicago
Kansas
University of Kansas Medical Center
Kansas City
Massachusetts
Beth Israel Deaconess Medical Center - Nephrology
Boston
Tufts Medical Center
Boston
Maryland
General Clinical Research Center, University of Maryland Baltimore
Baltimore
Michigan
Quest Research Institute
Farmington Hills
Minnesota
University of Minnesota -Health Clinical Research Unit
Minneapolis
Mayo Clinic - Rochester
Rochester
Nevada
DaVita Clinical Research
Las Vegas
New York
Columbia University Medical Center
New York
Pennsylvania
Geisinger Clinic
Danville
Perelman Center for Advanced Medicine - Nephrology
Philadelphia
Tennessee
Nephrology Clinical Trials Center
Nashville
Vermont
UVM Medical Center - 1 South Prospect Street
Burlington
Washington
Swedish Center for Comprehensive Care
Seattle
Other Locations
Belgium
Universite Catholique de Louvain, Cliniques universitaires Saint-Luc (UCLouvain)
Brussels
Universitaire Ziekenhuizen Leuven
Leuven
Canada
St. Joseph's Healthcare - Hamilton
Hamilton
MUHC - Montreal Children's Hospital
Montreal
France
Hopital de la Cavale Blanche
Brest
Necker Hospital
Paris
Germany
Charité - Klinik für Nephrologie und Intensivmedizin der
Berlin
Universitaetsklinik Koeln Department II of Internal Medicine
Cologne
Netherlands
UMCG - Nephrology
Groningen
Erasmus Medisch Centrum - Nephrology
Rotterdam
Puerto Rico
FDI Clinical Research - San Juan
San Juan
Spain
Hospital Fundacion Jimenez Diaz
Madrid
United Kingdom
Queen Elizabeth Hospital Birmingham
Birmingham
King's College Hospital
London
Royal Free NHS Trust
London
St Georges University Hospitals NHS Foundation Trust
London
Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital - Nephrology
Newcastle Upon Tyne
Northern General Hospital
Sheffield
Time Frame
Start Date: 2024-12-19
Completion Date: 2026-12-31
Participants
Target number of participants: 401
Treatments
Part A
Eligible participants will complete a single visit to complete a blood sample collection for PKD1/2 genotyping.
Part B
Participants who have completed all assessments in Part A and have a subset of variants in PKD1 will complete 1 year of follow-up.
Related Therapeutic Areas
Sponsors
Leads: Vertex Pharmaceuticals Incorporated